L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function

Diabetology and Metabolic Syndrome

Volumn 3, Issue 1, 2011, Pages

  Xia, Yunqiu ^a   Li, Qing ^a   Zhong, Weizhen ^a   Dong, Jing ^a   Wang, Zhulin ^a   Wang, Chunbo ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Carnitine; Mitochondria; Nonalcoholic Fatty Liver Disease (NAFLD); Type 2 Diabetes Mellitus

Indexed keywords

ACETYLCARNITINE; CARNITINE; FATTY ACID; GLYCOGEN; INSULIN; STREPTOZOCIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DISEASE MODEL; ELECTRON MICROSCOPY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSULIN BLOOD LEVEL; LIVER CELL; LIVER WEIGHT; MALE; MICROSCOPY; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 81055124193     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-3-31     Document Type: Article

References (43)

1. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N, Diabetes 2001 50 1844 1850 10.2337/diabetes.50.8.1844 11473047 (Pubitemid 33641605)
2. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Bloomgarden ZT, Diabetes Care 2005 28 1518 1523 10.2337/diacare.28.6.1518 15920084 (Pubitemid 40756729)
3. Banting lecture 1988. Role of insulin resistance in human disease. Reaven GM, Diabetes 1988 37 1595 1607 10.2337/diabetes.37.12.1595 3056758 (Pubitemid 19004941)
4. Nonalcoholic steatohepatitis. Sheth SG, Gordon FD, Chopra S, Ann Intern Med 1997 126 137 145 9005748 (Pubitemid 27058588)
5. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Lupi R, Dotta F, Marselli L, Del GS, Masini M, Santangelo C, Patane G, Boggi U, Piro S, Anello M, et al. Diabetes 2002 51 1437 1442 10.2337/diabetes.51.5.1437 11978640 (Pubitemid 34826609)
6. [Toxic liver injuries - a current view on pathogenesis. Part II]. Bak M, Kicinska-Krogulska M, Czerniak P, Michowicz A, Krakowiak A, Med Pr 2011 62 203 210 21698879
7. Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo. Wang S, Kamat A, Pergola P, Swamy A, Tio F, Cusi K, Metabolism 2011
8. Carnitine in type 2 diabetes. Mingrone G, Ann N Y Acad Sci 2004 1033 99 107 10.1196/annals.1320.009 15591007 (Pubitemid 39656742)
9. Obesity, inflammation, and the potential application of pharmaconutrition. Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ, McClave SA, Nutr Clin Pract 2008 23 16 34 10.1177/011542650802300116 18203961 (Pubitemid 351438965)
10. Carnitine biosynthesis: nutritional implications. Broquist HP, Borum PR, Adv Nutr Res 1982 4 181 204 6801934
11. Isolation of a malonyl-CoA-sensitive CPT/beta-oxidation enzyme complex from heart mitochondria. Kerner J, Bieber L, Biochemistry 1990 29 4326 4334 10.1021/bi00470a010 2350540 (Pubitemid 20153632)
12. Carnitine and derivatives in rat tissues. Pearson DJ, Tubbs PK, Biochem J 1967 105 953 963 16742571
13. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson MP, Antioxid Redox Signal 2010 13 1763 1811 10.1089/ars.2009.3074 20446769
14. Carnitine metabolism and its regulation in microorganisms and mammals. Rebouche CJ, Seim H, Annu Rev Nutr 1998 18 39 61 10.1146/annurev.nutr.18.1.39 9706218 (Pubitemid 28366860)
15. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. Broderick TL, Quinney HA, Lopaschuk GD, J Biol Chem 1992 267 3758 3763 1740427
16. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessi M, Spiga C, Astara G, et al. Nutrition 2006 22 136 145 10.1016/j.nut.2005.06.003 16459226 (Pubitemid 43188803)
17. L-carnitine improves glucose disposal in type 2 diabetic patients. Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De GA, Gasbarrini G, J Am Coll Nutr 1999 18 77 82 10067662 (Pubitemid 29088689)
18. Insulin resistance in skeletal muscles of patients with diabetes mellitus. Beck-Nielsen H, Diabetes Metab Rev 1989 5 487 493 10.1002/dmr. 5610050602 2670489 (Pubitemid 19212480)
19. Quantitation of the effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. Lysiak W, Lilly K, DiLisa F, Toth PP, Bieber LL, J Biol Chem 1988 263 1151 1156 3335535 (Pubitemid 18039914)
20. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Rossignol DA, Frye RE, Mol Psychiatry 2011
21. Mitochondrial dysfunction in the liver of type 2 diabetic Goto-Kakizaki rats: improvement by a combination of nutrients. Hao J, Shen W, Sun L, Long J, Sharman E, Shi X, Liu J, Br J Nutr 2011 1 8
22. Effect of carnitine supplementation on mitochondrial enzymes in liver and skeletal muscle of rat after dietary lipid manipulation and physical activity. Karanth J, Jeevaratnam K, Indian J Exp Biol 2010 48 503 510 20795369
23. L-carnitine therapy in home parenteral nutrition patients with abnormal liver tests and low plasma carnitine concentrations. Bowyer BA, Miles JM, Haymond MW, Fleming CR, Gastroenterology 1988 94 434 438 3121432 (Pubitemid 18054781)
24. L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Romano M, Vacante M, Cristaldi E, Colonna V, Gargante MP, Cammalleri L, Malaguarnera M, Dig Dis Sci 2008 53 1114 1121 10.1007/s10620-007-9983-1 17939042 (Pubitemid 351379846)
25. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li VG, Galvano F, Am J Gastroenterol 2010 105 1338 1345 10.1038/ajg.2009.719 20068559
26. Perturbation of polyamine catabolism can strongly affect root development and xylem differentiation. Tisi A, Federico R, Moreno S, Lucretti S, Moschou PN, Roubelakis-Angelakis KA, Angelini R, Cona A, Plant Physiol 2011 157 200 215 10.1104/pp.111.173153 21746808
27. Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. Cao Y, Wang YX, Liu CJ, Wang LX, Han ZW, Wang CB, Clin Invest Med 2009 32 13 E19 19178874
28. Histopathology of nonalcoholic fatty liver disease. Brunt EM, Tiniakos DG, World J Gastroenterol 2010 16 5286 5296 10.3748/wjg.v16.i42.5286 21072891
29. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Luo J, Quan J, Tsai J, Hobensack CK, Sullivan C, Hector R, Reaven GM, Metabolism 1998 47 663 668 10.1016/S0026-0495(98)90027-0 9627363 (Pubitemid 28265168)
30. Non-alcoholic steatohepatitis: another disease of affluence. James O, Day C, Lancet 1999 353 1634 1636 10.1016/S0140-6736(99)00163-4 10335777 (Pubitemid 29224514)
31. Lipoprotein lipase activity and intramuscular triglyceride stores after long-term high-fat and high-carbohydrate diets in physically trained men. Kiens B, Essen-Gustavsson B, Gad P, Lithell H, Clin Physiol 1987 7 1 9 10.1111/j.1475-097X.1987.tb00628.x 3545651 (Pubitemid 17004437)
32. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. RANDLE PJ, GARLAND PB, HALES CN, NEWSHOLME EA, Lancet 1963 1 785 789 13990765
33. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Bloomgarden ZT, Diabetes Care 2005 28 1518 1523 10.2337/diacare.28.6.1518 15920084 (Pubitemid 40756729)
34. Role of cannabinoids in the development of fatty liver (steatosis). Purohit V, Rapaka R, Shurtleff D, AAPS J 2010 12 233 237 10.1208/s12248-010- 9178-0 20204561
35. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Lupi R, Dotta F, Marselli L, Del GS, Masini M, Santangelo C, Patane G, Boggi U, Piro S, Anello M, et al. Diabetes 2002 51 1437 1442 10.2337/diabetes.51.5.1437 11978640 (Pubitemid 34826609)
36. L-carnitine in dialysis patients. Ahmad S, Semin Dial 2001 14 209 217 10.1046/j.1525-139X.2001.00055.x 11422928 (Pubitemid 33720854)
37. Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Srinivas SR, Prasad PD, Umapathy NS, Ganapathy V, Shekhawat PS, Am J Physiol Gastrointest Liver Physiol 2007 293 1046 G1053 10.1152/ajpgi.00233.2007 17855766 (Pubitemid 350106559)
38. Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid. Cha YS, Asia Pac J Clin Nutr 2008 17 Suppl 1 306 308 18296364
39. Role of carnitine in hepatic ketogenesis. McGarry JD, Robles-Valdes C, Foster DW, Proc Natl Acad Sci USA 1975 72 4385 4388 10.1073/pnas.72.11.4385 1060116
40. Enzymes of triacylglycerol synthesis and their regulation. Coleman RA, Lee DP, Prog Lipid Res 2004 43 134 176 10.1016/S0163-7827(03)00051-1 14654091 (Pubitemid 37492937)
41. Primary and secondary carnitine deficiency syndromes. Pons R, De Vivo DC, J Child Neurol 1995 10 Suppl 2 8 24 8576570
42. Primary carnitine deficiency. Scholte HR, Rodrigues PR, de Jonge PC, Luyt-Houwen IE, Hedwig M, Verduin M, Ross JD, J Clin Chem Clin Biochem 1990 28 351 357 2199596 (Pubitemid 20183142)
43. Delaying the mitochondrial decay of aging. Ames BN, Ann N Y Acad Sci 2004 1019 406 411 10.1196/annals.1297.073 15247055 (Pubitemid 38951346)